New Publication Validates Stemcells, Inc.’s SC Proven® Reagents for Automated Production and Cell-Based Screening
Complete the form below to unlock access to ALL audio articles.
StemCells, Inc. has announced publication of a collaborative study which used commercially available SC Proven serum-free cell culture media for the reproducible and robust production of large numbers of genetically stable, self-renewing cells that retain true multi-potent biological function over extended culture periods.
This work overcomes a key hurdle to the use of non-immortalized cells for regenerative medicine, and demonstrates the utility of human tissue-derived neural stem (NS) cells as a scalable platform for cell-based drug discovery and drug screening applications.
The paper was published in a special edition of Neurochemistry International dedicated to “The Potential of Stem Cells for 21st Century Neuroscience” and is available online at http://www.sciencedirect.com/science/article/pii/S0197018611002452.
“We can now say our serum-free RHB-A® and RHB-Basal® culture media are ‘Automation Proven’ for large-scale production of billions of stem cells per week for regenerative medicine applications,” said Stewart Craig, Ph.D., Senior Vice President, Development & Operations at StemCells, Inc.
Craig continued, “This work by our scientists and their collaborators underscores the rationale for, and the advantage of, using well defined, serum-free and where possible animal component-free reagents for cell culture and cell-based assays because it eliminates contaminants that cause culture variability and that impair assay performance.”
Furthermore, Hook et al used the CompacT SelecT™ system from TAP Biosystems for the at scale automated dispensing of NS cells into multi-well plates with onward incubation for in vitro cell-based drug screening assays. These assays also used the serum-free RHB-A and RHB-Basal culture media along with the serum-free and animal component-free NDiff® N2-AF and NDiff® N27-AF culture supplements.
This newly reported data adds to that previously presented by the Company at international regenerative medicine and drug screening meetings in which the same SC Proven reagents were used for the automated scale-up, production and assay screening of human induced pluripotent stem (iPS) cell derived NS cell lines.
The tools and technologies showcased in this work are components of the platform that StemCells has integrated to help partners address all phases of drug discovery and development, from initial screening through in vitro characterization, and then in vivo validation of lead candidates using the actual human target cell (http://www.stemcellsinc.com/Tools-and Technologies/Drug-Discovery-and-Development.htm).
